President Trump's newly-signed "Most-Favored-Nation" pricing policy has exposed a critical vulnerability in India's pharmaceutical sector – its decades-long over-dependence on the US market.The executive order signed May 12 implies that Americans will pay no more than the lowest price available globally for medicines, with a tight timeline: the US Health and Human Services will communicate price targets within 30 days, and companies have six months after that to demonstrate "significant progress" or face “aggressive measures”.
.png)
